• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations.
 

Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations.

Options
  • Details
BORIS DOI
10.48620/87901
Date of Publication
September 2025
Publication Type
Article
Division/Institute

Clinic of Rheumatolog...

University Library Be...

Contributor
Pluma, Andrea
Hamroun, Sabrina
Rüegg, Linda
Clinic of Rheumatology and Immunology
Cecchi, Irene
Kramer, Malte
Perez-Garcia, Luis Fernando
Rivero, Tania
University Library Bern, Medical Library
Finckh, Axel
Meissner, Yvette
Förger, Frauke
Clinic of Rheumatology and Immunology
Subject(s)

600 - Technology::610...

Series
Annals of the Rheumatic Diseases
ISSN or ISBN (if monograph)
1468-2060
0003-4967
Publisher
BMJ Publishing Group
Language
en
Publisher DOI
10.1016/j.ard.2025.02.021
PubMed ID
40240264
Description
Objectives
This study aimed to summarise and update evidence to inform the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.Methods
A systematic literature review (SLR) was performed, including keywords on reproduction, adverse pregnancy outcomes (APOs), and lactation. Two appraised SLRs were the basis for the SLR on drug safety in men. If sufficient data were available, a meta-analysis was performed on maternal drug exposure and the risk of APOs.Results
Of 6680 screened articles, 255 were included in the final analysis. In pregnancy, most evidence was available for biologic disease-modifying antirheumatic drugs (bDMARDs). Meta-analyses with adjusted risk estimates did not reveal APOs or serious infant infections to be associated with tumour necrosis factor inhibitor (TNFi) use. Data on non-TNFi bDMARDs did not raise concerns. In bDMARD-exposed infants, no serious adverse effects to rotavirus live vaccination were reported. Safety of Bacille Calmette-Guérin vaccination in TNFi-exposed infants could be a concern in the first 6 months of life. Regarding oral glucocorticoids, the SLR and meta-analysis using adjusted risk estimates found a dose-dependent association with an increased risk of preterm birth. Nonsteroidal anti-inflammatory drug use could reversibly reduce fecundability. Concerning lactation, available data on various bDMARDs was reassuring. In male patients, available evidence on methotrexate and most other drugs did not reveal adverse effects on sperm quality or birth outcomes. Cyclophosphamide remains the only drug that causes a dose-dependent irreversible infertility.Conclusions
This SLR provides up-to-date evidence to guide the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/210151
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
1-s2.0-S0003496725008143-main.pdftextAdobe PDF1.14 MBAttribution-NonCommercial-NoDerivatives (CC BY-NC-ND 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 396f6f [24.09. 11:22]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo